Positron emission tomography in the evaluation of lymphoma

Seminars in Nuclear Medicine

Volumn 34, Issue 3, 2004, Pages 166-179

  Israel, Ora ^a,b   Keidar, Zohar ^a   Bar Shalom, Rachel ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUORODEOXYGLUCOSE F 18; GALLIUM 67; PREDNISONE; PROCARBAZINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; FIBROSIS; FOLLOW UP; HEALTH STATUS; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LYMPHOMA; MEDICAL ASSESSMENT; METABOLISM; MINIMAL RESIDUAL DISEASE; NECROSIS; NONHODGKIN LYMPHOMA; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; SALVAGE THERAPY; SCINTIGRAPHY; TREATMENT OUTCOME;

EID: 3042760773     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2004.03.002     Document Type: Article

References (102)

1. Boring C., Squires T., Tong T., et al. Cancer statistics. Ca Canc J Clin. 44:1994;7-26
2. Smith S.D., Rubin C.M., Horvath A., et al. Non-Hodgkin's lymphoma in children. Semin Oncol. 17:1990;113-119
3. Schoder H., Meta J., Yap C., et al. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med. 42:2001;1139-1143
4. Hagemeister F.B. Hodgkin's disease the next decade. Leuk Lymph. 21:1996;53-61
5. Canellos G.P. Current strategies for early Hodgkin's disease. Ann Oncol. 7:(suppl 4):1996;S91-S93
6. Aisenberg A.C. Coherent view of Non-Hodgkin's lymphoma. J Clin Oncol. 13:1995;2656-2675
7. Armitage J.O., Wisenburger D.D., Hutchins M., et al. Chemotherapy for diffuse large cell lymphoma - rapidly responding patients have more durable remissions. J Clin Oncol. 4:1986;160-164
8. Coiffier B., Bryon P., Berger F., et al. Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80). J Clin Oncol. 4:1986;147-153
9. Hoh C.K., Glaspy J., Rosen P., et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med. 38:1997;343-348
10. O'Doherty M.J., Macdonald E.A., Barrington S.F., et al. Positron emission tomography in the management of lymphomas. Clin Oncol. 14:2002;415-426
11. Jerusalem G., Beguin Y., Fassotte M.F., et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica. 86:2001;266-273
12. Cook G.J.R., Fogelman I., Maisey M.N. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning Potential for error in interpretation. Semin Nucl Med. 26:1996;308-314
13. Barrington S.F., O'Doherty M.J. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging. 30:(suppl 1):2003;S117-S127
14. Brink I., Reinhardt M.J., Hoegerle S., et al. Increased metabolic activity in the thymus gland studied with 18F-FDG PET Age dependency and frequency after chemotherapy. J Nucl Med. 42:2001;591-595
15. Nakahara T., Fujii H., Ide M., et al. FDG uptake in the morphologically normal thymus Comparison of FDG positron emission tomography and CT. Br J Radiol. 74:2001;821-824
16. Sugawara Y., Fisher S.J., Zasadny K.R., et al. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol. 16:1998;173-180
17. Sugawara Y., Zasadny K.R., Kison P.V., et al. Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy PET imaging results. J Nucl Med. 40:1999;1456-1462
18. Bar-Shalom R., Yefremov N., Guralnik L., et al. Clinical performance of PET-CT in evaluation of cancer Additional value for diagnostic imaging and patient management. J Nucl Med. 44:2003;1200-1209
19. Freudenberg L.S., Antoch G., Schutt P., et al. FDG-PET-CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging. 31:2004;325-329
20. Cohade C., Mourtzikos K.A., Clark D.P., et al. Utility of FDG PET-CT in patients with cutaneous T-cell lymphomas initial evaluation. J Nucl Med. 44:2003;84P. (abstr)
21. Bar- Shalom R., Valdivia A.Y., Blaufox M.D. PET imaging in oncology. Semin Nucl Med. 30:2000;150-185
22. Paul R. Comparison of Fluorine-18-2-fluorodeoxyglucose and Gallium-67 citrate imaging for detection of lymphoma. J Nucl Med. 28:1987;288-292
23. Newman J.S., Francis I.R., Kaminski M.S., et al. Imaging of lymphoma with PET with 2-[F-18]fluoro-2-deoxy-D-glucose Correlation with CT. Radiology. 190:1994;111-116
24. Jerusalem G.H., Beguin Y.P. Positron emission tomography in non-Hodgkin's lymphoma (NHL) Relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL. Clin Lymphoma. 3:2002;56-61
25. Friedberg J.W., Chengazi V. PET scans in the staging of lymphoma Current status. Oncologist. 8:2003;438-447
26. Leskinen-Kallio S., Ruotsalainen U., Nagren K., et al. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma A PET study. J Nucl Med. 32:1991;1211-1218
27. Hoffmann M., Kletter K., Diemling M., et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol. 10:1999;1185-1189
28. Moog F., Bangerter M., Diederichs C.G., et al. Lymphoma Role of whole-body 2-deoxy-2-[F-18] fluoro-D-glucose (FDG) PET in nodal staging. Radiology. 203:1997;795-800
29. Stumpe K.D.M., Urbinelli M., Steinert H.C., et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma Effectiveness and comparison with computed tomography. Eur J Nucl Med. 25:1998;721-728
30. Hoffmann M., Chott A., Puspok A., et al. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) does not visualize follicular lymphoma of the duodenum. Ann Hematol. 83:2004;276-281
31. Hoffmann M., Kletter K., Becherer A., et al. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology. 64:2003;336-340
32. Lapela M., Leskinen S., Minn H.R.I., et al. Increased glucose metabolism in untreated Non-Hodgkin's lymphoma A study with positron emission tomography and Fluorine-18-Fluorodeoxyglucose. Blood. 86:1995;3522-3527
33. Rodriguez M., Rehn S., Ahlstrom H., et al. Predicting malignancy grade with PET in Non-Hodgkin's lymphoma. J Nucl Med. 36:1995;1790-1796
34. Okada J., Yoshikawa K., Itami M., et al. Positron emission tomography using Fluorine-18-fluorodeoxyglucose in malignant lymphoma a comparison with proliferative activity. J Nucl Med. 33:1992;325-329
35. Okada J., Yoshikawa K., Imazeki K., et al. The use of FDG-PET in the detection and management of malignant lymphoma Correlation of uptake with prognosis. J Nucl Med. 32:1991;686-691
36. Okada J., Oonish H., Yoshikawa K., et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med. 8:1994;187-191
37. Armitage J.O. Drug therapy Treatment of non Hodgkin's lymphoma. N Engl J Med. 328:1993;1023-1030
38. Partridge S., Timothy A., O'Doherty M.J., et al. 2-Fluorine-18-fluoro-2- deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease influence on patient management in a single institution. Ann Oncol. 11:2000;1273-1279
39. Romer W., Schwaiger M. Positron emission tomography in diagnosis and therapy monitoring of patients with lymphoma. Clin Positron Imaging. 1:1998;101-110
40. Sandrasegaran K., Robinson P.J., Selby P. Staging of lymphoma in adults. Clin Oncol. 94:1994;149-161
41. Weihrauch M.R., Re D., Bischoff S., et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol. 81:2002;20-25
42. Bangerter M., Moog F., Buchmann I., et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol. 9:1998;1117-1122
43. Sasaki M., Kuwabara Y., Koga H., et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision-making for malignant lymphoma. Ann Nucl Med. 16:2002;337-345
44. Jerusalem G., Warland V., Majjar F., et al. Whole-body 18F-FDG-PET for the evaluation of patients with Hodgkin's disease and Non-Hodgkin's lymphoma. Nucl Med Commun. 20:1999;13-20
45. Delbeke D., Martin W.H., Morgan D.S., et al. 2-deoxy-2-[F-18]fluoro-D- glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma. Mol Imaging Biol. 4:2002;105-114
46. Buchmann I., Reinhardt M., Elsner K., et al. 2-(fluorine-18)fluoro-2- deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer. 91:2001;889-899
47. Jerusalem G., Beguin Y., Najjar F., et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol. 2:2001;825-830
48. Najjar F., Hustinx R., Jerusalem G., et al. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL). Cancer Biother Radiopharm. 16:2001;297-304
49. Moog F., Bangerter M., Diederichs C.G., et al. Extranodal malignant lymphoma Detection with FDG PET versus CT. Radiology. 206:1998;475-481
50. Moog F., Bangerter M., Kotzerke J., et al. 18-F-Fluorodeoxyglucose- positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol. 16:1998;603-609
51. Moog F., Kotzerke J., Reske S.N. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med. 40:1999;1407-1413
52. Rini J.N., Leonidas J.C., Tomas M.B., et al. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med. 44:2003;1072-1074
53. Carr R., Barrington S.F., Madan B., et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 91:1998;3340-3346
54. Kostakoglu L., Goldsmith S.J. Positron emission tomography in lymphoma Comparison with computed tomography and Gallium-67 single photon emission computed tomography. Clin Lymphoma. 1:2000;67-74
55. Klose T., Leidl R., Buchmann I., et al. Primary staging of lymphomas cost-effectiveness of FDG-PET versus computed tomography. Eur J Nucl Med. 27:2000;1457-1464
56. Schiepers C., Filmont J.E., Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 30:(suppl 1):2003;S82-S88
57. Radford J.A., Cowan R.A., Flanagan M., et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol. 6:1988;940-946
58. Surbone A., Longo D.L., DeVita V.T., et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy significance and management. J Clin Oncol. 6:1988;1832-1837
59. Reske S.N. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging. 30:(suppl 1):2003;S89-S96
60. Iosilevsky G., Front D., Bettman L., et al. Uptake of Gallium-67 citrate and [2-3H] deoxyglucose in the tumor model, following chemotherapy and radiotherapy. J Nucl Med. 26:1985;278-282
61. Coiffier B. How to interpret the radiological abnormalities that persist after treatment in non-Hodgkin's lymphoma patients? Ann Oncol. 10:1999;1141-1143
62. Jochelson M., Mauch P., Balikian J., et al. The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol. 3:1985;637-640
63. Cremerius U., Fabry U., Neuerburg J., et al. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun. 19:1998;1055-1063
64. Zinzani P.L., Magagnoli M., Chierichetti F., et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol. 10:1999;1181-1184
65. Jerusalem G., Beguin Y., Fassotte M.F., et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 94:1999;429-433
66. Lavely W.C., Delbeke D., Greer J.P., et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys. 57:2003;307-315
67. Mikhaeel N.G., Timothy A.R., O'Doherty M.J., et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leuk Lymphoma. 39:2000;543-553
68. Spaepen K., Stroobants S., Dupont P., et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol. 19:2001;414-419
69. Naumann R., Vaic A., Beuthien-Baumann B., et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol. 115:2001;793-800
70. Montravers F., McNamara D., Landman-Parker J., et al. [(18)F]FDG in childhood lymphoma clinical utility and impact on management. Eur J Nucl Med Mol Imaging. 29:2002;1155-1165
71. Weihrauch M.R., Re D., Scheidhauer K., et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood. 98:2001;2930-2934
72. Dittmann H., Sokler M., Kollmannsberger C., et al. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep. 8:2001;1393-1399
73. Spaepen K., Stroobants S., Dupont P., et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol. 115:2001;272-278
74. de Wit M., Bohuslavizki K.H., Buchert R., et al. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol. 12:2001;29-37
75. Hueltenschmidt B., Sautter-Bihl M.L., Lang O., et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer. 91:2001;302-310
76. Mikhaeel N.G., Timothy A.R., Hain S.F., et al. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol. 11:(suppl 1):2000;147-150
77. de Wit M., Bumann D., Beyer W., et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol. 8:(suppl 1):1997;57-60
78. Cremerius U., Fabry U., Kroll U., et al. Clinical value of FDG PET for therapy monitoring of malignant lymphoma-results of a retrospective study in 72 patients. Nuklearmedizin. 38:1999;24-30
79. Bar Shalom R., Mor M., Yefremov N., et al. The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment. Sem Nucl Med. 31:2001;177-190
80. Bangerter M., Kotzerke J., Griesshammer M., et al. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol. 38:1999;799-804
81. Jerusalem G., Beguin Y., Fassotte M.F., et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol. 14:2003;123-130
82. Front D., Bar-Shalom R., Mor M., et al. Aggressive non-Hodgkin lymphoma Early prediction of outcome with Ga67 scintigraphy. Radiology. 214:2000;253-257
83. Hoekstra O.S., Ossenkoppele G.J., Golding R., et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18- fluorodeoxyglucose scintigraphy. J Nucl Med. 34:1993;1706-1710
84. Dimitrakopoulou-Strauss A., Strauss L.G., Goldschmidt H., et al. Evaluation of tumor metabolism and multi-drug resistance in patients with treated malignant lymphomas. Eur J Nucl Med. 22:1995;434-442
85. Wiedmann E., Baican B., Hertel A., et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymphoma. 34:1999;545-551
86. Jerusalem G., Beguin Y., Fassotte M.F., et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica. 85:2000;613-618
87. Kostakoglu L., Coleman M., Leonard J.P., et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 43:2002;1018-1027
88. Spaepen K., Stroobants S., Dupont P., et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 13:2003;1356-1363
89. Torizuka T., Nakamura F., Kanno T., et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 31:2004;22-28
90. Becherer A., Mitterbauer M., Jaeger U., et al. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia. 16:2002;260-267
91. Cremerius U., Fabry U., Wildberger J.E., et al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 30:2002;103-111
92. Filmont J.E., Czernin J., Yap C., et al. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest. 124:2003;608-613
93. Spaepen K., Stroobants S., Dupont P., et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood. 102:2003;53-59
94. Torizuka T., Zasadny K.R., Kison P.V., et al. Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy Evaluation with FDG PET. J Nucl Med. 41:2000;999-1005
95. Shen Y.Y., Kao A., Yen R.F. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Oncol Rep. 9:2002;321-325
96. Van den Bossche B., Lambert B., De Winter F., et al. 18-FDG PET versus high-dose Ga-67 scintigraphy for restaging and treatment follow up of lymphoma patients. Nucl Med Commun. 23:2002;1079-1083
97. Wirth A., Seymour J.F., Hicks R.J., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, Gallium-67 scintigraphy and conventional staging for Hodgkin's disease and Non-Hodgkin's lymphoma. Am J Med. 112:2002;262-268
98. Kostakoglu L., Leonard J.P., Kuji I., et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer. 94:2002;879-888
99. Bar-Shalom R., Yefremov N., Haim N., et al. Camera-based FDG PET and Ga-67 SPECT in evaluation of lymphoma comparative study. Radiology. 227:2003;353-360
100. Rini J.N., Manalili E.Y., Hoffman M.A., et al. F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin's disease. Clin Nucl Med. 27:2002;. 572-527
101. Zijlstra J.M., Hoekstra O., Raijmaker P.G.H., et al. 18-FDG positron emission tomography versus Ga-67 scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma. Brit J Haemat. 123:2003;454-462
102. Kostakoglu L., Goldsmith S. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow up of lymphoma Is it time to shift gears? Eur J Nucl Med. 27:2000;1564-1578